Bank of America analyst Allen Lutz has adjusted the price target for Waystar (WAY, Financial), lowering it from $51 to $48 while maintaining a Buy rating. This revision comes in light of recent survey data from the firm, which indicates a deceleration in healthcare systems' willingness to overhaul their revenue cycle software strategies.
Despite this slowdown, Waystar is reportedly gaining increased recognition among hospitals, although the anticipated signing of contracts may experience delays. These delays are attributed to a cautious approach in the market, influenced by uncertainties related to tariffs. Lutz conveyed to investors a tempered optimism about Waystar's growing presence in the healthcare sector, though emphasizing the adjusted timing expectations for future agreements.
